Skip to main content Accessibility help
  • Print publication year: 2014
  • Online publication date: June 2014

Chapter 24 - Interaction between cerebral small vessel disease and neurodegenerative changes

from Section 3 - Clinical aspects of cerebral small vessel disease


1. Jellinger KA, Attems J. Neuropathology and general autopsy findings in nondemented aged subjects. Clin Neuropathol 2012;31:87–98.
2. Polvikoski TM, Van Straaten EC, Barkhof F, et al. Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. Neurology 2010;75:2071–2078.
3. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association Work Groups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:263–269.
4. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association Work Groups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:270–279.
5. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS–ADRDA criteria. Lancet Neurol 2007;6:734–746.
6. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 2010;9:1118–11127.
7. Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS–AIREN international workshop. Neurology 1993;43:250–260.
8. Hejl A, Hogh P, Waldemar G. Potentially reversible conditions in 1000 consecutive memory clinic patients. J Neurol Neurosurg Psychiatry 2002;73:390–394.
9. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54:S4–S9.
10. Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord 2002;16:203–212.
11. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001;357:169–175.
12. O’Brien JT, Erkinjuntti T, Reisberg B, et al. Vascular cognitive impairment. Lancet Neurol 2003;2:89–98.
13. Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke–Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006;37:2220–2241.
14. Gorelick PB, Scuteri A, Black SE, et al. Vascular Contributions to Cognitive Impairment and Dementia: a Statement for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:2672–2713.
15. Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000;59:23–30.
16. Staekenborg SS, Van Straaten EC, van der Flier WM, et al. Small vessel versus large vessel vascular dementia: risk factors and MRI findings. J Neurol 2008;255:1644–1651.
17. Gold G, Giannakopoulos P, Herrmann FR, Bouras C, Kovari E. Identification of Alzheimer and vascular lesion thresholds for mixed dementia. Brain 2007;130:2830–2836.
18. Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 2004;62:1148–1155.
19. Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer’s disease. Lancet 1999;354:919–920.
20. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997;277:813–817.
21. Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 2002;1:13–21.
22. Sluimer JD, van der Flier WM, Karas GB, et al. Accelerating regional atrophy rates in the progression from normal aging to Alzheimer’s disease. Eur Radiol 2009;19:2826–2833.
23. Lehmann M, Koedam EL, Barnes J, et al. Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer’s disease. Neurobiol Aging 2012;33:672.
24. Frisoni GB, Pievani M, Testa C, et al. The topography of grey matter involvement in early and late onset Alzheimer’s disease. Brain 2007;130:720–730.
25. Koedam EL, Lehmann M, van der Flier WM, et al. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 2011;21:2618–2625.
26. Fernando MS, Ince PG. Vascular pathologies and cognition in a population-based cohort of elderly people. J Neurol Sci 2004;226:13–17.
27. Gouw AA, Seewann A, Vrenken H, et al. Heterogeneity of white matter hyperintensities in Alzheimer’s disease: postmortem quantitative MRI and neuropathology. Brain 2008;131:3286–3298.
28. Gouw AA, Seewann A, van der Flier WM, et al. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 2011;82:126–135.
29. Barkhof F, Scheltens P. Is the whole brain periventricular? J Neurol Neurosurg Psychiatry 2006;77:143–144.
30. Fazekas F, Kleinert R, Roob G, et al. Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol 1999;20:637–642.
31. Goos JD, Kester MI, Barkhof F, et al. Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke 2009;40:3455–3460.
32. Vernooij MW, van der Lugt A, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology 2008;70:1208–1214.
33. Vernooij MW, Haag MD, van der Lugt A, et al. Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study. Arch Neurol 2009;66:714–720.
34. Goos JD, van der Flier WM, Knol DL, et al. Clinical relevance of improved microbleed detection by susceptibility-weighted magnetic resonance imaging. Stroke 2011;42:1894–1900.
35. Ihara M, Polvikoski TM, Hall R, et al. Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer’s disease, and dementia with Lewy bodies. Acta Neuropathol 2010;119:579–589.
36. Okamoto Y, Yamamoto T, Kalaria RN, et al. Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts. Acta Neuropathol 2012;123:381–394.
37. Kalaria RN, Erkinjuntti T. Small vessel disease and subcortical vascular dementia. J Clin Neurol 2006;2:1–11.
38. DeCarli CS. When two are worse than one: stroke and Alzheimer disease. Neurology 2006;67:1326–1327.
39. Staekenborg SS, Koedam EL, Henneman WJ, et al. Progression of mild cognitive impairment to dementia: contribution of cerebrovascular disease compared with medial temporal lobe atrophy. Stroke 2009;40:1269–1274.
40. Verdelho A, Madureira S, Moleiro C, et al. White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. Neurology 2010;75:160–167.
41. Smith EE, Egorova S, Blacker D, et al. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Arch Neurol 2008;65:94–100.
42. Prins ND, van Dijk EJ, den Heijer T, et al. Cerebral white matter lesions and the risk of dementia. Arch Neurol 2004;61:1531–1534.
43. Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke 2010;41:600–606.
44. Vermeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215–1222.
45. Prins ND, van Dijk EJ, den Heijer T, et al. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain 2005;128:2034–2041.
46. Van der Flier WM, Van Straaten EC, Barkhof F, et al. Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. Stroke 2005;36:2116–2120.
47. Schmidt R, Ropele S, Enzinger C, et al. White matter lesion progression, brain atrophy, and cognitive decline: the Austrian Stroke Prevention Study. Ann Neurol 2005;58:610–616.
48. Schmidt R, Ropele S, Ferro J, et al. Diffusion-weighted imaging and cognition in the Leukoariosis And DISability in the elderly study. Stroke 2010;41:e402–e408.
49. Van Norden AG, van Uden IW, de Laat KF, van Dijk EJ, de Leeuw FE. Cognitive function in small vessel disease: the additional value of diffusion tensor imaging to conventional magnetic resonance imaging: the RUN DMC study. J Alzheimers Dis 2012;32:667–676.
50. Kalaria RN. Cerebrovascular disease and mechanisms of cognitive impairment: evidence from clinicopathological studies in humans. Stroke 2012;43:2526–2534.
51. Brundel M, de Bresser J, van Dillen JJ, Kappelle LJ, Biessels GJ. Cerebral microinfarcts: a systematic review of neuropathological studies. J Cereb Blood Flow Metab 2012;32:425–436.
52. Cordonnier C, van der Flier WM. Brain microbleeds and Alzheimer’s disease: innocent observation or key player? Brain 2011;134:335–344.
53. Cordonnier C, van der Flier WM, Sluimer JD, et al. Prevalence and severity of microbleeds in a memory clinic setting. Neurology 2006;66:1356–1360.
54. Pettersen JA, Sathiyamoorthy G, Gao FQ, et al. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook Dementia Study. Arch Neurol 2008;65:790–795.
55. Goos JD, Teunissen CE, Veerhuis R, et al. Microbleeds relate to altered amyloid-β metabolism in Alzheimer’s disease. Neurobiol Aging 2012;33:1011–1019.
56. Van der Vlies AE, Goos JD, Barkhof F, Scheltens P, van der Flier WM. Microbleeds do not affect rate of cognitive decline in Alzheimer disease. Neurology 2012;79:763–769.
57. Van der Flier WM. Clinical aspects of microbleeds in Alzheimer’s disease. J Neurol Sci 2012;322:56–58.
58. Henneman WJ, Sluimer JD, Cordonnier C, et al. MRI biomarkers of vascular damage and atrophy predicting mortality in a memory clinic population. Stroke 2009;40:492–498.
59. Altmann-Schneider I, Trompet S, de Craen AJ, et al. Cerebral microbleeds are predictive of mortality in the elderly. Stroke 2011;42:638–644.
60. Sperling RA, Jack CR, Jr., Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Work Group. Alzheimers Dement 2011;7:367–385.
61. Boche D, Zotova E, Weller RO, et al. Consequence of Aβ immunization on the vasculature of human Alzheimer’s disease brain. Brain 2008;131:3299–3310.
62. Damoiseaux JS, Smith SM, Witter MP, et al. White matter tract integrity in aging and Alzheimer’s disease. Hum Brain Mapp 2009;30:1051–1059.
63. Clerx L, Visser PJ, Verhey F, Aalten P. New MRI markers for Alzheimer’s disease: a meta-analysis of diffusion tensor imaging and a comparison with medial temporal lobe measurements. J Alzheimers Dis 2012;29:405–429.
64. Spilt A, Weverling-Rijnsburger AW, Middelkoop HA, et al. Late-onset dementia: structural brain damage and total cerebral blood flow. Radiology 2005;236:990–995.
65. Binnewijzend MA, Kuijer JP, Benedictus MR, et al. Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: a marker for disease severity. Radiology 2013;267:221–230.
66. Allan LM, Rowan EN, Firbank MJ, et al. Long term incidence of dementia, predictors of mortality and pathological diagnosis in older stroke survivors. Brain 2011;134:3716–3727.
67. Lewis H, Beher D, Cookson N, et al. Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-β42 peptide in vascular dementia. Neuropathol Appl Neurobiol 2006;32:103–118.
68. Bastos-Leite AJ, van der Flier WM, Van Straaten EC, et al. The contribution of medial temporal lobe atrophy and vascular pathology to cognitive impairment in vascular dementia. Stroke 2007;38:3182–3185.
69. Firbank MJ, Burton EJ, Barber R, et al. Medial temporal atrophy rather than white matter hyperintensities predict cognitive decline in stroke survivors. Neurobiol Aging 2007;28:1664–1669.
70. Vogels RL, Oosterman JM, van Harten B, et al. Neuroimaging and correlates of cognitive function among patients with heart failure. Dement Geriatr Cogn Disord 2007;24:418–423.
71. Gemmell E, Bosomworth H, Allan L, et al. Hippocampal neuronal atrophy and cognitive function in delayed poststroke and aging-related dementias. Stroke 2012;43:808–814.
72. Firbank MJ, He J, Blamire AM, et al. Cerebral blood flow by arterial spin labeling in poststroke dementia. Neurology 2011;76:1478–1484.
73. Huang KL, Lin KJ, Ho MY, et al. Amyloid deposition after cerebral hypoperfusion: evidenced on [(18)F]AV-45 positron emission tomography. J Neurol Sci 2012;319:124–129.
74. Grimmer T, Faust M, Auer F, et al. White matter hyperintensities predict amyloid increase in Alzheimer’s disease. Neurobiol Aging 2012;33:2766–2773.
75. Deramecourt V, Slade JY, Oakley AE, et al. Staging and natural history of cerebrovascular pathology in dementia. Neurology 2012;78:1043–1050.
76. Van Veluw SJ, Zwanenburg JJ, Engelen-Lee J, et al. In vivo detection of cerebral cortical microinfarcts with high-resolution 7T MRI. J Cereb Blood Flow Metab 2013;33:322–329.
77. Pantoni L, Basile AM, Pracucci G, et al. Impact of age-related cerebral white matter changes on the transition to disability – the LADIS study: rationale, design and methodology. Neuroepidemiology 2005;24:51–62.
78. Inzitari D, Simoni M, Pracucci G, et al. Risk of rapid global functional decline in elderly patients with severe cerebral age-related white matter changes: the LADIS study. Arch Intern Med 2007;167:81–88.
79. Inzitari D, Pracucci G, Poggesi A, et al. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (Leukoaraiosis And DISability) study cohort. BMJ 2009;339:2477.
80. Van der Flier WM, Van Straaten EC, Barkhof F, et al. Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study. J Neurol Neurosurg Psychiatry 2005;76:1497–1500.
81. Jokinen H, Lipsanen J, Schmidt R, et al. Brain atrophy accelerates cognitive decline in cerebral small vessel disease: the LADIS study. Neurology 2012;78:1785–1792.
82. De Leeuw FE, Korf E, Barkhof F, Scheltens P. White matter lesions are associated with progression of medial temporal lobe atrophy in Alzheimer disease. Stroke 2006;37:2248–2252.
83. Murray ME, Graff-Radford NR, Ross OA, et al. Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011;10:785–796.
84. Van de Pol LA, Hensel A, van der Flier WM, et al. Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2006;77:439–442.
85. De Bresser J, Brundel M, Conijn MM, et al. Visual cerebral microbleed detection on 7T MR imaging: reliability and effects of image processing. AJNR Am J Neuroradiol 2013;34:E61–E64.